• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by TRACON Pharmaceuticals Inc.

    10/31/24 5:00:02 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCON alert in real time by email
    RW 1 rule477_withdrawal_appli.htm RW RW

    TRACON Pharmaceuticals, Inc.

    124 Washington Street

    Foxborough, MA 02035

    October 31, 2024

    VIA EDGAR

    United States Securities and Exchange Commission

    Division of Corporation Finance

    100 F Street, N.E.

    Washington, D.C. 20549

    Attention: Tim Buchmiller

     

    Re: TRACON Pharmaceuticals, Inc.

    Rule 477 Application for Withdrawal of Registration Statement on Form S-1

    Filed on April 12, 2024

    File No. 333-278661

    Ladies and Gentlemen:

    Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), TRACON Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that, effective as of the date first set forth above or at the earliest practicable date thereafter, the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-278661) initially filed with the Commission on April 12, 2024, together with all exhibits thereto (the “Registration Statement”). The grounds upon which the Company is making this application for withdrawal are that the Company’s board of directors and stockholders have approved the liquidation and dissolution of the Company pursuant to a plan of dissolution, and accordingly the Company does not intend to proceed with the offering of the common stock proposed to be registered by the Registration Statement at this time.

    The Company confirms that the Registration Statement has not been declared effective and no securities have been or will be issued or sold pursuant to the Registration Statement or the prospectus contained therein.

    Pursuant to Rule 477(b) under the Securities Act, the Company understands that this request for withdrawal of the Registration Statement will be deemed granted as of the date hereof unless the Company receives notice from the Commission within 15 days of the date hereof that such request will not be granted.

    The Company also requests, in accordance with Rule 457(p) under the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use for the Company’s account.

    Thank you for your assistance. If you should have any questions, please contact Matthew Browne of Cooley LLP at (858) 550-6045, or in his absence, Anitha Anne at (415) 693-2250.

    Very truly yours,

    TRACON Pharmaceuticals, Inc.

    By:

    /s/ Craig R. Jalbert

    Name:

    Craig R. Jalbert

    Title:

    President and Chief Executive Officer


    cc:

    Scott Brown, TRACON Pharmaceuticals, Inc.
    Matthew Browne, Cooley LLP
    Anitha Anne, Cooley LLP


    Get the next $TCON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCON

    DatePrice TargetRatingAnalyst
    2/23/2022$10.00Outperform
    Baird
    More analyst ratings

    $TCON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TRACON Pharmaceuticals Announces it Will Wind Down Operations

      SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in

      7/30/24 4:44:46 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform

      The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company will focus on exploring strategic alternatives, that may include a variety of strategic transactions such as a reverse merger, acquisition, sale of all assets, or other strategic transactions leveraging its in-house Product Development Platform of CRO-independent clinical trial execution SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully

      7/1/24 9:00:00 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

      Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science c

      6/11/24 8:00:00 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    Financials

    Live finance-specific insights

    See more
    • TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

      SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "With ENVASARC fully enrolled we are focused on leveraging our Product Development Platform to generate non-dilutive capital through either an additional license or by replacing a CRO and executi

      5/14/24 4:01:00 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

      SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results. Date:May 14, 2024Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Conference Call:In order t

      5/7/24 4:01:00 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

      SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "We are on track to complete enrollment of 80 patients treated with single agent envafolimab in the ongoing pivotal ENVASARC trial later this quarter. We expect to report updated

      3/5/24 4:02:00 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    SEC Filings

    See more
    • SEC Form 15-12G filed by TRACON Pharmaceuticals Inc.

      15-12G - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

      11/7/24 4:05:49 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.

      EFFECT - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

      11/4/24 12:15:04 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.

      EFFECT - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

      11/4/24 12:15:09 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    Leadership Updates

    Live Leadership Updates

    See more
    • TRACON Pharmaceuticals Announces it Will Wind Down Operations

      SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in

      7/30/24 4:44:46 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors

      SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Carol Lam to its Board of Directors. "We are very pleased to welcome Carol to our Board of Directors," said Dr. Charles Theuer, President and Chief Executive Officer of TRACON. "She brings a global perspective on technology development acquired through her extensive experience as deputy General Counsel

      10/13/21 8:00:00 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

      SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and the granting of an inducement equity award to Dr. Marczi. "We are very pleased to welcome Brenda to the senior management team at TRACON," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "

      7/20/21 8:05:00 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Lazar David E.

      3 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

      5/13/24 5:00:43 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brown Scott B. was granted 3,500 shares, increasing direct ownership by 16% to 25,128 units (SEC Form 4)

      4 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

      3/13/24 5:59:38 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Theuer Charles was granted 7,000 shares, increasing direct ownership by 2% to 406,417 units (SEC Form 4)

      4 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

      3/13/24 5:56:13 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Baird initiated coverage on TRACON Pharmaceuticals with a new price target

      Baird initiated coverage of TRACON Pharmaceuticals with a rating of Outperform and set a new price target of $10.00

      2/23/22 4:50:05 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on TRACON Pharmaceuticals with a new price target

      Alliance Global Partners initiated coverage of TRACON Pharmaceuticals with a rating of Buy and set a new price target of $13.00

      6/4/21 8:08:23 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tracon Pharmaceuticals upgraded by BTIG Research with a new price target

      BTIG Research upgraded Tracon Pharmaceuticals from Neutral to Buy and set a new price target of $14.00

      4/16/21 8:36:58 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

      SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

      11/14/24 8:51:58 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

      4/5/24 4:10:26 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

      3/19/24 11:20:05 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care